摘要 |
The invention provides compounds of the formula (0) or salts or tautomers or N-oxides or solvates thereof for use in the prophylaxis or treatment of disease states and conditions such as cancers mediated by cyclin-dependent kinase and glycogen synthase kinase-3. In formula (0): X is a group R<SUP>1</SUP>-A-NR<SUP>4</SUP>- or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO<SUB>2</SUB>, C-O, NR<SUP>g</SUP>(C-O) or O(C-O) wherein R<SUP>g </SUP>is hydrogen or C<SUB>1-4 </SUB>hydrocarbyl optionally substituted by hydroxy or C<SUB>1-4 </SUB>alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R<SUP>1 </SUP>is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C<SUB>1-8 </SUB>hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, C<SUB>1-4 </SUB>hydrocarbyloxy, amino, mono- or di-C<SUB>1-4 </SUB>hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO<SUB>2</SUB>; R<SUP>2 </SUP>is hydrogen; halogen; C<SUB>1-4 </SUB>alkoxy (e.g. methoxy); or a C<SUB>1-4 </SUB>hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C<SUB>1-4 </SUB>alkoxy (e.g. methoxy); R<SUP>3 </SUP>is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R<SUP>4 </SUP>is hydrogen or a C<SUB>1-4 </SUB>hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C<SUB>1-4 </SUB>alkoxy (e.g. methoxy).
|